A5054519252- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Prostate Cancer Treatment and Research
- Urological Disorders and Treatments
- Prostate Cancer Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Renal cell carcinoma treatment
- Urologic and reproductive health conditions
- Cancer Immunotherapy and Biomarkers
- Ureteral procedures and complications
- Sexual Differentiation and Disorders
- Genetic factors in colorectal cancer
- Cardiac, Anesthesia and Surgical Outcomes
- Esophageal Cancer Research and Treatment
- Genetic Syndromes and Imprinting
- Renal and related cancers
- Colorectal Cancer Surgical Treatments
- Gut microbiota and health
- Pelvic and Acetabular Injuries
- Hormonal and reproductive studies
- Renal and Vascular Pathologies
- Immune cells in cancer
- Pelvic floor disorders treatments
- Ferroptosis and cancer prognosis
- Nutrition and Health in Aging
Cleveland Clinic
2016-2025
Memorial Sloan Kettering Cancer Center
2018-2024
Kidney Associates
2023
Ohio Gastroenterology and Liver Institute
2022
Cleveland Clinic Lerner College of Medicine
2017-2020
New York Proton Center
2019-2020
Molecular Oncology (United States)
2020
Case Western Reserve University
2017
Medical College of Wisconsin
2011
University of Wisconsin Carbone Cancer Center
2010
The adrenal-restrictive HSD3B1(1245A) allele limits extragonadal dihydrotestosterone synthesis, whereas the adrenal-permissive HSD3B1(1245C) augments synthesis. Retrospective studies have suggested an association between allele, frequency of which is highest in white men, and early development castration-resistant prostate cancer (CRPC).To examine CRPC using prospective data.The E3805 Chemohormonal Therapy vs Androgen Ablation Randomized Trial for Extensive Disease Prostate Cancer (CHAARTED)...
Abstract Loss of imprinting (LOI) is an epigenetic alteration involving loss parental origin-specific expression at normally imprinted genes. A LOI for Igf2, a paracrine growth factor, important in cancer progression. Epigenetic modifications may be altered by environmental factors. However, not known whether changes occur with aging prostate and other tissues susceptible to development. We found Igf2 occurs specifically the mouse associated increased during aging. In older animals,...
<h3>Importance</h3> The variant<i>HSD3B1</i>(1245C) allele enhances dihydrotestosterone synthesis and predicts resistance to androgen-deprivation therapy (ADT) for biochemically recurrent prostate cancer after prostatectomy metastatic disease. Whether this is true radiotherapy unknown. <h3>Objective</h3> To determine whether the<i>HSD3B1</i>(1245C) worse clinical outcomes from ADT biochemical recurrence radiotherapy. <h3>Design, Setting, Participants</h3> Prostate Clinical Research...
The HSD3B1 (1245C) germline variant encodes for a gain-of-function missense in 3β-hydroxysteroid dehydrogenase isoenzyme 1 (3βHSD1) that results increased dihydrotestosterone synthesis from extragonadal precursors and is predictive of more rapid progression to castration-resistant prostate cancer (CRPC).
Objective: Sarcopenia, or the age-related loss of skeletal muscle mass and function, has been investigated as a potential marker adverse outcomes among surgical patients.Our aim was to assess for changes in psoas volume (PMV) following administration neoadjuvant chemotherapy (NAC) patients with bladder cancer examine whether PMV NAC are predictive perioperative complications, pathologic response survival.Methods: During period 2009-2013, undergoing radical cystectomy (RC) at our institution...
BACKGROUND. A common germline variant in HSD3B1(1245A>C) encodes for a hyperactive 3β-hydroxysteroid dehydrogenase 1 (3βHSD1) missense that increases metabolic flux from extragonadal precursor steroids to DHT synthesis prostate cancer. Enabling of by HSD3B1(1245C) predicts more rapid clinical resistance castration and sensitivity androgen inhibition. thus appears define subgroup patients who benefit blocking androgens. However, abiraterone, which is administered block androgens, steroidal...
Abstract Treatment paradigms for patients with upper tract urothelial carcinoma (UTUC) are typically extrapolated from studies of bladder cancer despite their distinct clinical and molecular characteristics. The advancement UTUC research is hampered by the lack disease-specific models. Here, we report establishment patient derived xenograft (PDX) cell line models that reflect genomic biological heterogeneity human disease. Models demonstrate high concordance corresponding tumors, invasive...
Non-muscle invasive bladder cancer (NMIBC) represents 70-80% patients with newly diagnosed cancer, and Bacillus Calmette-Guerin (BCG) remains a cornerstone treatment for intermediate high-risk NMIBC to prevent disease recurrence progression. However, many experience after induction BCG, posing significant challenges in the management of disease. We conducted single cell RNA sequencing on freshly collected samples, distinguishing between those naive BCG that recurred post-BCG treatment....
TPS896 Background: Concurrent chemoradiotherapy (CRT) is a recommended treatment option for pts with MIBC interested in bladder-preservation and/or not candidates radical cystectomy (RC). Systemic radio-sensitizing chemotherapy may have off target side effects and exploring novel agents radiation an unmet need. SG antibody drug conjugate (ADC) has shown efficacy metastatic urothelial cancer (UC). RAD-SG single-arm phase 1 trial investigating the concurrent administration of adaptive...
823 Background: Although Bacillus Calmette-Guérin (BCG) is widely used to treat bladder cancer, its mechanism still not fully understood. Tumor-infiltrating lymphocytes (TIL) have been postulated prognostic value in where presence of TIL signifies favorable outcomes. TILs play an important role the tumor immune microenvironment, mediating response tumorigenesis and immunotherapeutic drugs. Neutrophils are also key players initiation, development progression cancer. This study features...
822 Background: The human microbiome significantly influences the efficacy and safety of various medications. To integrate microbial metabolism into precision medicine, it is crucial to develop strain- molecule-specific computational models that can predict a patient's microbiome's ability metabolize chemotherapy drugs. This study evaluates potential urine, pellet, supernatant samples identify profiles metabolizing genes in patients with bladder cancer. Methods: Catheterized from six (5...
Abstract Background Folate and methyl‐group deficiency has been linked to prostate cancer susceptibility, yet the mechanisms underlying these observations are incompletely understood. The region of genome containing imprinted genes insulin‐like growth factor 2 ( Igf2 ) H19 , both which display oncogenic functions, may be particularly sensitive environmental influences. Methods To determine whether a methyl‐deficient diet impacts epigenetic controls at – locus, we placed C57BL/6 mice...
No AccessJournal of UrologyAdult Urology1 Sep 2017Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance Yaw A. Nyame, Nima Almassi, Samuel C. Haywood, Daniel J. Greene, Vishnu Ganesan, Charles Dai, Joseph Zabell, Chad Reichard, Hans Arora, Anna Zampini, Alice Crane, Hettel, Ahmed Elshafei, Khaled Fareed, Robert Stein, Ryan K. Berglund, Michael Gong, Stephen Jones, Eric Klein, Andrew Stephenson NyameYaw Nyame ,...
Increased oxidative stress and concordant DNA methylation changes are found during aging in many malignant processes including prostate cancer. has been shown to inhibit methyltransferase vitro assays, but whether this occurs vivo is unknown. To generate increased we utilized mice containing mutations the CuZnSOD (Sod1) gene, a major superoxide dismutase mammals. 8-hydroxy-2'-deoxyguanosine, an adduct indicating damage, was liver tissues at 2 12 mo Sod1+/- compared controls. Prostate from...